Berberine

Property	Information
Drug Name	Berberine
FDA Approval	No
Used for	Glioblastoma Multiforme (GBM)
Clinical Trial Phase	Pre-clinical (in vitro and in vivo studies)
Clinical Trial Explanation	Not specified
Common Side Effects	Not specifically listed for GBM treatment; generally well-tolerated but can include gastrointestinal discomfort at high doses.
OS without	Not explicitly mentioned; refer to specific studies for detailed metrics.
OS with	Studies suggest enhancement of temozolomide efficacy in resistant GBM cases, potentially improving overall survival rates.
PFS without	Not specified
PFS with	Not specified
Usefulness Rating	Not rated
Usefulness Explanation	Not specified
Toxicity Level	3
Toxicity Explanation	Not specified

Notes: Recent studies underscore Berberine's promising role against GBM, especially in temozolomide-resistant cases. Its broad pharmacological actions against cancer, including GBM, spotlight its potential as a multi-targeted therapeutic agent. Despite the promising laboratory and animal model results, further research is needed to fully understand its clinical implications and optimal usage in GBM treatment.

From Ben Williams Book: Not specified

Loading comments...